


PHARMACEUTICAL 2020

Viking Therapeutics Inc. Rank 33 of 362







RealRate

PHARMACEUTICAL 2020

Viking Therapeutics Inc. Rank 33 of 362

The relative strengths and weaknesses of Viking Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viking Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 230% points. The greatest weakness of Viking Therapeutics Inc. is the variable Revenues, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 138%, being 441% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	283,501
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,777
Liabilities, Non-Current	360
Other Assets	755
Other Compr. Net Income	435
Other Expenses	0
Other Liabilities	0
Other Net Income	6,908
Property and Equipment	0
Research and Development	23,559
Revenues	0
Selling, General and Administrative Expense	9,128

Output Variable	Value in 1000 USD
Assets	284,256
Liabilities	7,137
Expenses	32,687
Stockholders Equity	277,119
Net Income	-25,779
Comprehensive Net Income	-25,562
Economic Capital Ratio	138%

